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Abstract Rheumatoid arthritis (RA) is a chronic autoim-
mune disease affecting 0.5–1% of the population world-
wide. The disease has a heterogeneous character,
including clinical subsets of anti-citrullinated protein
antibody (ACPA)-positive and APCA-negative disease.
Although the pathogenesis of RA is poorly understood,
progress has been made in identifying genetic factors that
contribute to the disease. The most important genetic risk
factor for RA is found in the human leukocyte antigen
(HLA) locus. In particular, the HLA molecules carrying
the amino acid sequence QKRAA, QRRAA, or RRRAA at
positions 70–74 of the DRβ1 chain are associated with the
disease. The HLA molecules carrying these “shared
epitope” sequences only predispose for ACPA-positive
disease. More than two decades after the discovery of
HLA-DRB1 as a genetic risk factor, the second genetic
risk factor for RAwas identified in 2003. The introduction
of new techniques, such as methods to perform genome-
wide association has led to the identification of more than
20 additional genetic risk factors within the last 4 years,
with most of these factors being located near genes
implicated in immunological pathways. These findings
underscore the role of the immune system in RA
pathogenesis and may provide valuable insight into the
specific pathways that cause RA.
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Abbreviations
ACPA Anti-citrullinated protein antibody
NIMA Non-inherited maternal antigen
NIPA Non-inherited paternal antigen
PAD Peptidylarginine deiminase
PADI4 Peptidylarginine deiminase type 4
PTPN22 Protein tyrosine phosphatase non-receptor type
22
RA Rheumatoid arthritis
RF Rheumatoid factor
RhD Rhesus D
SNP Single-nucleotide polymorphism
STAT4 Signal transducer and activator of transcription
4
SE Shared epitope
TNF Tumor necrosis factor
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3
Introduction
Rheumatoid arthritis
Rheumatoid arthritis (RA) is characterized by the chronic
inflammation of synovial joints, and affects 0.5–1% of the
adult population worldwide (Silman and Pearson 2002).
This inflammation can affect any synovial-lined diarthro-
dial joint (Imboden 2009), although, small joints of the
hands and feet are most commonly affected. Larger joints
like the shoulder and the knee can also be involved, but this
varies according to the individual. Radiographic joint
damage accumulates at a constant rate over time when left
untreated (Wolfe and Sharp 1998), and erosion of the joint
surface eventually causes joint deformity and loss of
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DOI 10.1007/s00251-011-0528-6function, which is associated with significant disability and
premature mortality (Majithia and Geraci 2007; Silman and
Pearson 2002). The definition of RA is phenotypic and was
developed on the basis of a consensus procedure by clinical
experts, resulting in the 1987 and 2010 Rheumatoid
Arthritis Classification Criteria (Aletaha et al. 2010; Arnett
et al. 1988).
Clinical subsets of ACPA-positive and ACPA-negative RA
patients
The clinical course of RA is extremely variable, showing a
wide spectrum of clinical manifestations ranging from mild
and self-limiting disease to rapidly progressive inflamma-
tion, joint destruction, and severe physical disability (Lee
and Weinblatt 2001). The heterogeneous character of the
disease results in differential responses to a range of
therapies, including anti-tumor necrosis factor (anti-TNF)
therapy (Plenge and Criswell 2008). A sub-classification of
RA could be helpful to predict clinical outcomes of
therapies. One way to sub-classify the phenotype RA could
be achieved on the basis of serologic factors, such as RA-
associated autoantibodies rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA). RF is not unique to
RA, whereas ACPA are highly specific for RA. ACPA are
antibodies directed against citrullinated proteins, while
citrullination is a physiologic process occurring under
different conditions including inflammation. Citrullination
is established by the conversion of arginine into citrullin by
peptidylarginine deiminase (PAD) (Makrygiannakis et al.
2006). ACPA are predictive for RA; 75% of the patients
with ACPA who presented with undifferentiated arthritis
will progress to RAwithin 3 years of follow-up (van Gaalen
et al. 2004a). Furthermore, patients with ACPA-positive
RA have a more aggressive clinical course as compared to
patients without ACPA (van Gaalen et al. 2004b). ACPA
can also induce and aggravate arthritis in mice, suggesting
that ACPA is involved in disease pathogenesis in humans
(Kuhn et al. 2006; Uysal et al. 2009).
Genetics in RA
The prevalence of RA in the general population is <1%;
however, among siblings, the prevalence increases to 2–4%
(Seldin et al. 1999). In addition, in cross-selectional twin
studies, concordance rates for RA were found between
12.3% and 15.4% for monozygotic twins, compared to 3.5%
for dizygotic twins (MacGregor et al. 2000). These sibling
and twin pair studies demonstrate that genetic factors have a
substantial impact on susceptibility to RA resulting in an
estimated genetic contribution to RA ranging from 50% to
60% (MacGregor et al. 2000;S e l d i ne ta l .1999).
HLA and the shared epitope hypothesis
The most important genetic risk factor for RA is the HLA
locus, which accounts for 30% to 50% of overall genetic
susceptibility to RA (Bowes and Barton 2008; Imboden
2009). In 1969, it was demonstrated that in mixed
lymphocyte cultures, peripheral blood lymphocytes from
patients with RA were non-reactive to peripheral blood
lymphocytes from other RA patients (Astorga and Williams
1969). Seven years later, in 1976, it was discovered that this
non-reactivity was due to the sharing of genes in the HLA
region (Stastny 1976), indicating a contribution of the HLA
region to RA. Stastny noted in 1978 that 78% of Caucasian
RA patients were HLA-DRw4 positive compared to 28% of
healthy controls (Stastny 1978). A decade later, it was
discovered that multiple RA risk alleles within the HLA-
DRB1 gene share a conserved amino acid sequence
(Gregersen et al. 1986a, b). This led to a new theory: the
“shared epitope” (SE) hypothesis (Gregersen et al. 1987).
Positions 70–74 in the third hypervariable region of the
DRβ1 chain of the RA-associated HLA-DRB1 molecules
all contain the conserved amino acids QKRAA, QRRAA,
or RRRAA. This sequence of amino acids is called the SE,
and the risk alleles carrying this sequence are widely known
as SE alleles. These specific amino acid sequences were not
only shared between HLA-DRB1*04 alleles but also between
the RA-associated HLA-DRB1*01 alleles (Gregersen et al.
1987). The OR for one SE allele is 4.37, whereas two copies
of HLA-DRB1 SE alleles have an OR of 11.79 (Huizinga et
al. 2005). Surprisingly, the association between SE-encoding
HLA-DRB1 alleles and RA was only observed for ACPA-
positive disease (Huizinga et al. 2005). Apparently, ACPA-
positive and ACPA-negative RA have different genetic risk
profiles (De Rycke et al. 2004;I m b o d e n2009; van der
Helm-van Mil and Huizinga 2008), indicating that not only
from clinical and pathogenic perspective but also from
genetic perspective, ACPA-positive versus ACPA-negative
RA represents two forms of RA.
Putative mechanisms behind the HLA SE in ACPA-positive
RA
Although it has been known for more than 30 years that the
HLA locus carries the most prominent genetic association
for RA, the underlying mechanism by which particular
HLA-DRB1 alleles predispose to the development of
ACPA-positive RA is still not understood, despite progress
in understanding the structure and function of HLA-DRB1
molecules. The HLA-DR molecule is a heterodimer
consisting of an alpha (DRA) and a beta chain (DRB),
both anchored in the membrane of antigen-presenting cells.
The function of HLA-DR molecules is to present antigenic
peptides to T lymphocytes. For efficient antigen presenta-
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both the peptide as well as the HLA-DR molecule itself.
The part of HLA-DR that binds to the peptide, the peptide-
binding groove, is composed of two α-helical walls and a
floor of β-pleated sheet (Brown et al. 1993). The SE is
situated in the α-helix wall of the peptide-binding groove
(Gregersen et al. 1987). In this position, the SE influences
peptide binding to the HLA molecule as well as T cell
presentation (Fig. 1). Therefore, it has been postulated that
the SE motif itself is directly involved in the pathogenesis
of RA by allowing the presentation of an arthritogenic
peptide to T cells (Gregersen et al. 1987; van der Helm-van
Mil et al. 2007). Unfortunately, this hypothesis has not yet
been confirmed by the identification of specific arthrito-
genic peptides that bind to SE HLA-DR molecules in RA,
although it has been reported that citrullinated peptides bind
to HLA-SE molecules for presentation to Tcells (Feitsma et
al. 2010; Hill et al. 2003). T cells that recognize
citrullinated antigen presented by HLA could subsequently
help B cells to secrete ACPA. However, several alternative
hypotheses regarding SE have been proposed that could
also explain the contribution of the HLA locus to RA.
These hypotheses include the idea that the HLA-SE
molecules shape the T cell repertoire to permit escape from
tolerance or survival of autoreactive clones, or serve as a
target for autoreactive T cells owing to molecular mimicry
with a pathogen, and even fail to bind an arthritogenic
peptide, leading to an inadequate tolerant immune response
(Firestein 2003). In ACPA-positive RA patients, SE alleles
have been shown to influence ACPA specificity by
predisposing to the development of antibodies against
citrullinated vimentin but not to the development of
antibodies against citrullinated fibrinogen. This indicates
that SE alleles act as classic immune response genes in the
ACPA response because they influence both the magnitude
and the specificity of this RA-specific antibody response
(Verpoort et al. 2007). Because of the heterogeneous nature
of RA, it is suggested that in addition to genetic factors,
environmental factors might be of importance as well for
the development of RA (Firestein 2003). Smoking has been
established as a relevant environmental risk factor for
ACPA-positive disease, especially in subjects carrying one
or two copies of the HLA-DRB1 SE (Kallberg et al. 2011;
Linn-Rasker et al. 2006). The association of ACPA-positive
RA and smoking could be explained by the observation of
citrullinated proteins in the lungs of smokers, which are
possibly well presented by HLA with SE (Makrygiannakis
et al. 2008).
Genetic risk factors in addition to HLA
Almost 30 years after the identification of HLA alleles as
a risk factor for RA, an RA-associated gene outside the
HLA region was recognized. It was not until 2003,
however, that the gene peptidylarginine deiminase type 4
(PADI4) was identified in a Japanese population as a
second risk factor for RA (Suzuki et al. 2003). Interest-
ingly, PADI genes encode the enzymes to change arginine
into citrulline, the target of ACPA. The discovery of
PADI4 as a risk factor was followed by the identification
of protein tyrosine phosphatase non-receptor type 22
(PTPN22) in 2004 (Begovich et al. 2004; Carlton et al.
2005;G r e g e r s e n2005). After 2004, the identification of
new genetic risk factors underwent an unexpected accel-
eration. One year later, in 2005, CTLA4 was found during
a candidate gene study (Plenge et al. 2005). In 2007, by
means of a candidate gene approach (Kurreeman et al.
2007), a novel genetic risk factor was identified in the
9q33 region of the genome containing TRAF1/C5;i tw a s
also detected concurrently in a genome-wide study (Plenge
et al. 2007b). Two more additional risk loci were
discovered in 2007, the signal transducer and activator of
transcription (STAT4) gene region on chromosome 2q,
following a mapping of genes under a linkage peak
(Remmers et al. 2007), as well as single-nucleotide
polymorphisms (SNPs) near the gene TNF-α induced
protein 3 (TNFAIP3), following genome-wide association
studies (Plenge et al. 2007a; Thomson et al. 2007). The
application of this latter technique allowed the identifica-
Fig. 1 The HLA-DR4 molecule with the position of the SE sequence.
The crystal structure of HLA-DRB1*04:01/DRA1*01:01 complexed
with a human collagen II-derived peptide (dark grey circles) shows the
peptide-binding groove created by the helical structures of the HLA-
DR alpha and beta chain with (indicated in red) the SE at peptide-
binding pocket 4 (Polyview-3D)
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forward (Plenge 2009). In 2008, another seven RA risk
loci genes, of which six were identified in a meta-analysis
of three genome-wide association study (GWAS) (Barton
et al. 2008; Raychaudhuri et al. 2008) were detected, with
the most significant finding localized in the CD40 gene
region. At the beginning of 2011, more than 30 established
RA risk loci were identified (Chen et al. 2011; Gregersen
et al. 2009; Raychaudhuri et al. 2009;S t a h le ta l .2010;
Zhernakova et al. 2011)( F i g .2).
GWAS studies rapidly expanded the number of SNPs
associated with ACPA-positive RA; however, this gave rise
to the question as to what could we learn from these
associations and whether we could use these SNPs to better
understand RA pathogenesis. Most of the identified SNPs
are located near genes that are linked to immunological
pathways, implicating—not surprisingly—immune-related
events as an important component of RA. The associated
genes are often linked to T or B cell activation or to
differentiation and cytokine signaling (Zhernakova et al.
2009). Some of the associated genes—for instance,
PADI4—are only found to be associated with RA. This
directly implicates differences in citrullination as a mech-
anism important for RA development. Other genetic
associations are shared between different autoimmune
diseases (Zhernakova et al. 2009). PTPN22, for example,
is linked to RA, systemic lupus erythematosus, type 1
diabetes, and other autoimmune diseases (Bottini et al.
2004; Jawaheer et al. 2003; Kyogoku et al. 2004). PTPN22
encodes a tyrosine phosphatase and is hypothesized to
affect the threshold for B and T cell receptor signaling
(Gregersen 2005). For many of the associated genes, the
immunological mechanism explaining the genetic associa-
tion is difficult to demonstrate. For most of the associated
loci, the functional SNP is still unknown. Identifying the
functional SNP is important for determining the effect of
the functional variation on gene expression and function,
while another complicating factor is the fact that most of
the proteins expressed by the associated genes play multiple
important roles in the immune system and affect different
immunological pathways. For example, genetic variants
near CD40 have been shown to be associated with RA
(Raychaudhuri et al. 2008). CD40 is a member of the TNF-
receptor family and is expressed on many different immune
cells including B cells, macrophages, and dendritic cells. It
is important not only for the priming of T cells and
activation of B cells but also for the activation of
macophages and dendritic cells. Furthermore, the expres-
sion of CD40 on RA synovial cells was hypothesized to
contribute to joint destruction (Peters et al. 2009). Dissect-
ing these different pathways in a human system to study
which pathways are important for RA pathogenesis is a
challenge, as it will be difficult to show which CD40-
expressing cell associated with certain CD40 genotypes is
primarily responsible for the enhanced risk to develop RA.
Like CD40, most of the identified genes play complex roles
in the immune system, indicating that even if it is
elucidated as to how a certain genetic variant influences
gene expression or function, it is still not known how it
contributes to disease. Thus, although the number of SNPs
associated with RA is rapidly expanding, the challenge for
the future will be to unravel the mechanisms by which the
proteins expressed by these genes contribute to RA
pathogenesis.
Genetic risk factors for ACPA-negative RA
Many HLA-DRB1 alleles are described as risk factors for
ACPA-positive RA. For ACPA-negative disease, the situ-
ation is clearly different, as only HLA-DR3 predisposes to
ACPA-negative RA (Irigoyen et al. 2005; Verpoort et al.
2005). Another risk factor for ACPA-negative RA—
interferon regulatory factor 5 (Sigurdsson et al. 2007)—
has been described, although this association could not be
replicated in other study populations (Garnier et al. 2007;
Rueda et al. 2006). Recently, it has been suggested that
neuropeptide S receptor gene polymorphisms might be
implicated in ACPA-negative RA susceptibility and its
clinical manifestations (D’Amato et al. 2010). Although
many more genetic risk factors have thus far been described
Fig. 2 Susceptibility genes for RA (Barton et al. 2008; Begovich et
al. 2004; Chen et al. 2011; Gregersen et al. 1987, 2009; Kurreeman et
al. 2007; Plenge et al. 2005, 2007a, b; Raychaudhuri et al. 2008, 2009;
Remmers et al. 2007; Stahl et al. 2010; Stastny 1978; Suzuki et al.
2003; Thomson et al. 2007; Zhernakova et al. 2011)
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this does not imply that genetic factors contribute more to
ACPA-positive RA. A recent study showed that the
heritability of RA among twin pairs for ACPA-positive RA
is 68% and for ACPA-negative RA it is 66% (van der
Woude et al. 2009). This suggests that the heritability of
ACPA-positive and ACPA-negative disease is comparable,
although for ACPA-negative disease, the genetic risk factors
remain to be identified since cohorts used for genetic risk
factors mainly consist of ACPA-positive RA patients.
Protection against the development of RA
Protection against RA is predominantly associated
with HLA-DRB1*13:01
In addition to HLA-DRB1 alleles that contribute to RA
susceptibility, other HLA-DRB1 alleles confer protection
against the disease. These protective HLA-DRB1 alleles are
more often present in healthy controls compared to RA
patients and have been categorized according to several
models. One of the classifications put forward in the
literature postulates that protection against RA is conferred
by the DERAA sequence at position 70–74 of the HLA-
DRB1 allele, which is at the same position on the HLA-
DRB1 alleles as the SE sequence. Likewise, other models
suggest that protection is conferred by isoleucine (I) at
position 67 (I67) (de Vries et al. 2002) or propose an
association mainly with aspartic acid (D) at position 70
(D70) (del Ricon and Escalante 1999; Mattey et al. 2001;
Reviron et al. 2001). Data from a recent study did not
support the hypothesis that I67 confers protection against
RA; in this study, only the presence of D70 appeared to
confer some degree of protection (Morgan et al. 2008). Due
to conflicting results, a meta-analysis was performed
involving four European populations with >2,800 patients
and >3,000 control subjects to investigate thoroughly which
HLA-DRB1 alleles were associated with protection against
ACPA-positive RA and ACPA-negative RA. To correct for
skewing due to this association, the analysis for ACPA-
positive RA was stratified for the SE alleles. Interestingly,
this study showed that the only association that conveyed
protection against ACPA-positive RA after stratification of
SE involved HLA-DRB1*13 alleles. The protective effect of
other classifications, including DERAA and D70, was no
longer present after the exclusion of HLA-DRB1*13. This
indicates that HLA-DRB1*13 rather than DERAA, D70, or
I67 is associated with protection. Among the DRB1*13
alleles, only DRB1*13:01 appeared to be associated with
protection. For ACPA-negative RA, no associations with
protective HLA-DRB1 alleles exist (van der Woude et al.
2010).
Non-inherited maternal antigen
In 1954, a biological effect of non-inherited maternal antigen
(NIMA) was reported for the first time. It was demonstrated
that rhesus D (RhD)-negative children were tolerant to the
RhD antigen if their mother was RhD positive (Owen et al.
1954). In addition to the RhD antigen, HLA is also
mentioned as NIMA in a study showing that haploidentical
NIMA-mismatched sibling transplants have a graft survival
rate similar to that of HLA identical siblings, whereas non-
inherited paternal antigen (NIPA)-mismatched sibling trans-
plants did as poorly as the recipients of maternal and paternal
grafts (Burlingham et al. 1998). Recently, it was shown that
HLA-DRB1 molecules that contain the amino acid sequence
DERAAwhen present as NIMA also have a protective effect
on the development of RA (Feitsma et al. 2007). By using a
cohort of Dutch RA patients together with their parents, it
was shown that the mothers of patients with RA had a
significantly lower frequency (16.1%) of DERAA-
containing HLA-DRB1 alleles than did the Dutch control
population (29.3%). In contrast, the frequencies of DERAA-
containing HLA-DRB1 alleles in fathers of the patients with
RA (26.2%) were comparable to the frequencies of DERAA-
containing HLA-DRB1 alleles in fathers of healthy controls.
These findings were replicated in an English cohort (Feitsma
et al. 2007). Due to the dominance of HLA-DRB1*13:01 in
DERAA-positive HLA alleles, it is not known whether the
NIMA effect derives from DERAA-containing HLA-DRB1
alleles or only from HLA-DRB1*13:01.I fr e p l i c a t e df u r t h e r ,
the finding that certain HLA-alleles—when seen as NIMA—
can protect offspring is highly interesting, as it suggests
directions in which to manipulate the immune system in
such a way that it will not be able to precipitate RA.
Conclusions: genetics and RA
The first genetic risk factor for RA was identified in
1978. After the discovery of this association between
HLA and RA, it took 25 years until PADI4,t h es e c o n d
genetic risk factor for RA, was identified. On the basis of
new techniques, the discovery of new genes associated
w i t hah i g hr i s ko fd e v e l o p i n gR Ai m p r o v e d .S i n c e2 0 0 4 ,
more than 20 genes have been found to be implicated,
mainly with ACPA-positive disease. The identification of
disease-associated genes could provide valuable insight
into the genetic variations pri o rt od i s e a s eo n s e ti no r d e rt o
identify the pathways important for RA pathogenesis.
Future challenges will be, among others, the translation of
genetic associations into biological pathways that are
responsible for RA, as this knowledge may prove to be
exceedingly useful for the invention of curative therapies
for RA.
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